Moisture Retention Testing: Corneometer Measurement & TEWL Clinical Study Protocol

Overview #

Moisture retention testing is not a marketing checkbox. It is the clinical backbone of every hydration claim your brand makes — and regulators in the EU, US, and China are increasingly scrutinizing exactly how those claims are substantiated. In our lab, we run Corneometer and TEWL measurements as a paired protocol on every hydration SKU we develop, because one number without the other tells an incomplete story. If you’re briefing us on a moisturizer, a barrier serum, or a hydrating essence, this is the testing framework we’ll be working from.

What Corneometer and TEWL Actually Measure — and Why You Need Both #

Corneometer measures capacitance-based skin hydration in the stratum corneum. The probe reads dielectric properties of the outermost skin layers, outputting an arbitrary unit (AU) value typically ranging from 0 to 120 AU. Dry skin usually reads below 30 AU. Well-hydrated skin sits between 45–70 AU depending on body site and ambient conditions. The number sounds precise. It isn’t always.

Here’s the problem we run into constantly: a formulation can spike Corneometer readings by loading up on humectants — glycerin at 5–8%, sodium hyaluronate at 0.1–0.5% — without actually improving barrier function. The skin looks hydrated on the probe. By hour 6, the reading has dropped back to baseline because nothing is sealing that moisture in. That’s where TEWL comes in.

Transepidermal water loss (TEWL), measured by Tewameter or VapoMeter, quantifies water vapor flux through the skin surface in g/m²/h. A healthy barrier on the forearm typically reads 5–10 g/m²/h. Compromised skin — eczema, post-procedure, over-exfoliated — can exceed 25 g/m²/h. When we’re developing a barrier-repair product, we want to see TEWL reduction, not just Corneometer increase. Both moving in the right direction together is the only result worth putting on a claim card.

We’ve had projects where the brand wanted to lead with “72-hour hydration.” The Corneometer data at T+72h looked fine. The TEWL data told us the barrier was actually slightly more compromised at that timepoint than baseline. We almost always push back on that brief. You can’t claim 72-hour hydration if your barrier is leaking more water at hour 72 than it was at hour zero.

Clinical Study Protocol: How We Structure the Measurement #

Our standard in-house hydration efficacy protocol follows a controlled single-center design. Subjects are acclimated in a controlled room at 20–22°C and 40–60% relative humidity for 30 minutes before any measurement. We don’t skip this step. Ambient humidity variation alone can shift Corneometer readings by 8–12 AU, which is enough to invalidate a study if you’re not careful.

The clinical reference we anchor our protocol design to: a double-blind, randomized, vehicle-controlled study (n=42, 8 weeks, forearm application twice daily) demonstrated a mean Corneometer increase of 28.4% from baseline in the active group versus 6.1% in the vehicle control, with TEWL reduction of 18.7% in the active group. That’s the kind of paired result that holds up to regulatory scrutiny. Single-endpoint studies — Corneometer only, no TEWL — are increasingly questioned by EU notified bodies when used to substantiate barrier claims.

Our standard protocol structure:

• Baseline measurement: T=0 (before first application)
• Acute measurements: T+0.5h, T+2h, T+4h post single application
• Chronic measurements: Week 2, Week 4, Week 8 after twice-daily use
• Washout period: minimum 7 days prior to study start, no actives on test site
• Minimum panel size: n=30 for a claim-grade result; we recommend n=40 as buffer for dropouts

One thing we require from our CRO partners: raw data export, not just summary statistics. We’ve had one CRO deliver a report with beautiful p-values and no underlying dataset. That report was useless for EU dossier submission. We now require full individual subject data as a contractual deliverable.

For brands targeting the EU market, the SCCS Scientific Opinion on cosmetic claim substantiation is the reference document. It’s not legally binding in the same way as the regulation, but notified bodies treat it as the de facto standard.

If you’re developing hydration-focused products and want to understand how this testing integrates with our broader active ingredient systems, our hydration and moisture formulation documentation covers the full ingredient-to-claim pipeline.

Regulatory Claim Substantiation: EU, US, and China Side by Side #

This is where most brand owners get surprised. The testing protocol is actually the easier part. The harder part is understanding what each market will accept as substantiation — and they don’t agree.

Under EU Cosmetics Regulation 1223/2009, cosmetic claims must be substantiated by evidence referenced in the Product Information File (PIF). “Moisturizing” and “hydrating” are considered functional claims. They require documented evidence — which in practice means a consumer perception study, an instrumental study, or both. The EU’s Common Criteria Regulation (EC) No 655/2013 sets the framework: claims must be truthful, evidenced, honest, fair, and not misleading. There’s no pre-approval process, but if your claim is challenged, you need that PIF ready within 72 hours of a competent authority request.

The FDA Cosmetics Guidelines take a different approach. In the US, “moisturizer” is a cosmetic claim and doesn’t require pre-market substantiation filing. But the FDA’s “drug-cosmetic” boundary is the real risk. Claims like “repairs the skin barrier” or “restores skin’s natural moisture factor” can push a product toward OTC drug territory, which triggers a completely different regulatory pathway. We flag this for every US-bound brief. The line is blurry and the FDA has sent warning letters over moisturizer claims that crossed it.

China’s NMPA Cosmetic Regulation is the most documentation-intensive of the three. Since the 2021 Cosmetic Supervision and Administration Regulation (CSAR) came into force, efficacy claims must be substantiated by testing conducted at NMPA-recognized institutions. “Moisturizing” (保湿) is a Category 2 ordinary cosmetic claim, but the substantiation requirements are real. You need human efficacy testing — Corneometer data from a recognized lab is the standard approach — and that data must be filed with your registration dossier. Registration timelines for ordinary cosmetics run 20–40 working days for domestic filing; imported products go through a longer pathway.

Honestly, most brands underestimate the China pathway. They assume that because “moisturizing” is a basic claim, the bar is low. It’s not low — it’s just different. The NMPA wants specific institutional testing, and if your CRO isn’t on their recognized list, the data doesn’t count.

Where Most Brands Get the Protocol Wrong #

The most common failure we see: brands run a Corneometer study at a CRO, get a positive result, and assume that’s sufficient for all three markets. It usually isn’t.

For EU submission, the study design needs to align with the claim. “24-hour hydration” requires a T+24h measurement. Sounds obvious. We’ve reviewed brand-submitted dossiers where the last timepoint was T+8h and the brand was claiming 24-hour efficacy. That’s a problem.

For China NMPA, the institution matters as much as the data. We’ve had clients come to us with perfectly good Corneometer studies from reputable European CROs — studies that would sail through EU review — and had to redo the testing at a China-recognized institution because the NMPA simply won’t accept foreign CRO data for domestic filing. That’s an extra 6–10 weeks and real cost. We now tell every brand targeting China upfront: budget for dual testing if you want to use the same data across markets.

The TEWL piece is still underused in US and China submissions. In the EU, barrier-related claims are increasingly expected to have TEWL support. In the US and China, it’s not yet required — but we include it anyway because it strengthens the overall claim package and protects the brand if claims are ever challenged.

One pilot batch situation worth mentioning: we ran a hydration study for a client using a ceramide-peptide barrier serum. The lab-scale formula showed excellent TEWL reduction — 22% at week 4. When we scaled to 200kg production, the emulsification shear profile changed enough that ceramide particle size distribution shifted. The week-4 TEWL result in the production batch was 11%. Still positive, still claimable, but not what the brand had briefed their marketing team on. We caught it in QC before the study was submitted. Not every factory does.

For brands developing barrier-repair or sensitive skin products, our barrier repair and sensitive skin formulation resources cover how we approach ingredient selection to support both efficacy and claim substantiation.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a hydration brief comes in — because the answer changes everything about how we structure the testing program.

If you’re launching in the EU first, we’ll design the clinical protocol to cover your specific claim timepoints from day one. “All-day hydration” needs T+8h data minimum. “72-hour hydration” needs T+72h. We build the study around the claim, not the other way around.

If China is in scope, we flag the dual-testing requirement immediately and build it into the project timeline. Adding 8 weeks at the end of a project because the NMPA won’t accept your CRO data is a painful way to learn this lesson.

For the US market, we focus on keeping claims on the cosmetic side of the drug-cosmetic line. “Moisturizes skin for up to 8 hours” — fine. “Restores the skin barrier” — we’ll want to discuss that one before it goes on pack.

The documentation package we prepare for brand partners includes: full Corneometer and TEWL raw datasets, statistical analysis report (mean, SD, p-values vs. baseline and vs. control), study protocol with IRB or ethics documentation where required, CRO accreditation certificates, and a claim substantiation summary formatted for PIF inclusion. For China-bound products, we coordinate with our recognized institution partners and include the institutional testing report in the dossier package.

Packaging matters too. Airless pump formats preserve hydration actives better than open-jar formats, but airless pump adds $0.40–$0.80 per unit at MOQ 1,000. Most indie brands absorb that cost once they understand the stability implications for their active system.

Frequently Asked Questions #

Q: Do we need both Corneometer and TEWL, or can we just run one?

For a basic moisturizing claim, Corneometer alone is technically sufficient in most markets. But if you’re making any barrier-related claim — “strengthens the skin barrier,” “reduces moisture loss” — you need TEWL data. We recommend running both on every hydration SKU regardless, because it costs relatively little to add TEWL to an existing Corneometer study and it gives you claim flexibility later.

Q: How many subjects do we actually need for a valid hydration study?

Minimum n=30 for a claim-grade result that will hold up to EU scrutiny. We target n=40 to account for dropouts — typical dropout rate in our 8-week studies runs 10–15%. Anything below n=25 and we’d advise against using the data for primary claim substantiation.

Q: Our brand wants to claim “72-hour hydration” — is that realistic to substantiate?

Yes, but the study design has to match. You need a T+72h Corneometer measurement after a single application, with subjects not reapplying the product or using any other moisturizer during that window. In our experience, most formulas show meaningful hydration retention at T+24h; getting a statistically significant result at T+72h requires a well-optimized occlusive-humectant system. We’ve achieved it with the right ceramide-glycerin-polyglutamic acid combination, but it’s not automatic.

Q: How long does the full testing and documentation process take before we can file in China?

For ordinary cosmetics with a moisturizing claim, budget 12–16 weeks from formula finalization to completed NMPA dossier. That includes 8 weeks of clinical testing at a recognized institution, 2 weeks for report finalization, and 2–4 weeks for dossier compilation. The actual NMPA review after filing runs 20–40 working days on top of that.

Q: Can we use the same clinical study data for EU, US, and China?

For EU and US, yes — the same study data can substantiate claims in both markets, provided the study design meets the EU Common Criteria standard (which is the higher bar). For China, no. The NMPA requires testing conducted at a recognized domestic institution. You’ll need a separate China-specific study, or a study run at a recognized institution from the start if China is in scope.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.